


What is claimed is:

1. A compound of Formula (I), or a salt, solvate or hydrate thereof



wherein

each of R^1 and R^2 is independently selected from the group consisting of OH, OR^7 , and H, provided that at least one of R^1 and R^2 is -OH or - OR^7 ;

R^7 is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, aryl C_{1-6} alkyl and acyl;

R^3 is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{4-6} cycloalkenyl, halo, cyano, $-C(O)OR^8$, $-NR^9R^{10}$, $-S(O)_2NR^9R^{10}$, $-C(O)R^{11}$, $-OR^{12}$, $-S(O)_nR^{13}$, and optionally substituted heterocyclyl;

R^8 is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^9 and R^{10} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, or alternatively, R^9 and R^{10} together with the nitrogen atom to which they are attached form a 5-7 membered cyclic saturated or unsaturated ring;

R^{11} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, $-NR^9R^{10}$, and $-OR^{12}$;

each of R^{12} and R^{13} is independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;

R^6 is selected from the group consisting of H, halo, hydroxyl, alkoxy, optionally substituted C_{1-6} alkyl, halogenated alkyl; optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, and optionally substituted aryl C_{1-6} alkyl;

n is an integer having a value of 0, 1 or 2;

s is an integer having a value of 0, 1 or 2;

t is an integer having a value of 0 to 6;

R^5 is selected from the group consisting of H, halo, optionally substituted C_{1-6} alkyl, $-C(O)OR^{14}$, $-C(O)NR^{15}R^{16}$, aryl and $-C_{1-6}$ alkylaryl;

R^{14} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^{15} and R^{16} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl; alternatively R^{15} and R^{16} together with the nitrogen to which they are attached, form a 5-7 membered cyclic saturated or unsaturated ring;

R^4 is selected from the group consisting of H, halo, cyano, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, $-(CR^{18}R^{19})_tCOOR^8$, $-(CR^{18}R^{19})_tOC(O)R^8$, $-(CR^{18}R^{19})_tNR^9R^{10}$, $-(CR^{18}R^{19})_tC(O)NR^9R^{10}$, $-(CR^{18}R^{19})_tNR^9C(O)R^8$, $-(CR^{18}R^{19})_tS(O)_2NR^9R^{10}$, $-(CR^{18}R^{19})_tCOR^{11}$, $-(CR^{18}R^{19})_tCH(O)$, $-(CR^{18}R^{19})_tOR^{12}$, $-(CR^{18}R^{19})_tS(O)_sR^{13}$, optionally substituted heterocyclic, and optionally substituted heterocyclic C_{1-6} alkyl; and

each of R^{18} and R^{19} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl.

2. The compound according to claim 1 wherein R^1 and R^2 are each OH.

3. The compound according to claim 1 wherein one of R^1 and R^2 is OH and the other is H.
4. The compound according to claim 1 wherein one of R^1 and R^2 is OH and the other is OR^7 .
5. The compound according to claim 1 wherein each of R^1 and R^2 is OR^7 .
6. The compound according to any one of claims 1-4, or 5 wherein R^7 is an optionally substituted C_{1-6} alkyl.
7. The compound according to claim 6 wherein R^7 methyl.
8. The compound according to claim 6 wherein R^7 is C_{1-4} alkyl substituted with $NR^{22}R^{23}$ wherein each of R^{22} and R^{23} is independently selected from H or a C_{1-3} alkyl.
9. The compound according to claim 8 where R^7 is $-(CH_2)_3NH_2$.
10. The compound according to any one of claims 1 to 9, wherein R^3 is selected from the group consisting of optionally substituted C_{3-6} alkyl, optionally substituted C_{3-6} alkenyl, optionally substituted C_{3-6} alkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted C_{3-6} cycloalkyl and optionally substituted C_{3-6} cycloalkenyl.
11. The compound according to claim 10 wherein R^3 is selected from the group consisting of optionally substituted C_{3-6} alkyl and optionally substituted C_{3-6} cycloalkyl.
12. The compound according to any one of claims 1 to 11 wherein R^3 is selected from optionally substituted isopropyl, optionally substituted n-propyl, optionally substituted n-butyl, optionally substituted t-butyl, optionally substituted sec-butyl, optionally substituted n-pentyl, optionally substituted isopentyl, optionally substituted 2-methyl butyl, and optionally substituted n-hexyl.

13. The compound according to claim 12 wherein R^3 is isopropyl or *t*-butyl.
14. The compound according to claim 12 wherein R^3 is isopropyl.
15. The compound according to any one of claims 1 to 10 wherein R^3 is selected from the group consisting of optionally substituted cyclopropyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl ring.
16. The compound according to claim 15 wherein R^3 is cyclopentyl.
17. The compound according to any one of claims 1 to 16, wherein each of R^4 , R^5 , and R^6 is H.
18. The compound of claim 1 wherein:
 R^1 is selected from the group consisting of OH and OR^7 , wherein R^7 is optionally substituted C_{1-6} alkyl;
 R^2 is selected from the group consisting of OH and OR^7 , wherein R^7 is optionally substituted C_{1-6} alkyl;
 R^3 is optionally substituted C_{1-6} alkyl;
 R^4 is selected from the group consisting of H, $-(CR^{18}R^{19})_tCOOR^8$, and $-(CR^{18}R^{19})_tC(O)NR^9R^{10}$, wherein t is 0, R^8 is selected from the group consisting of H and optionally substituted C_{1-6} alkyl, R^9 is H and R^{10} is optionally substituted C_{1-6} alkyl;
 R^5 is H; and
 R^6 is selected from the group consisting of H and halo.
19. The compound according to claim 1 wherein:
 R^1 is selected from the group consisting of OH and OR^7 , wherein R^7 is C_{1-6} alkyl;
 R^2 is selected from the group consisting of OH and OR^7 , wherein R^7 is C_{1-6} alkyl substituted with $NR^{22}R^{23}$, wherein R^{22} and R^{23} are independently selected from H and C_{1-3} alkyl;
 R^3 is optionally substituted C_{1-6} alkyl;
 R^4 is selected from the group consisting of H, $-COOH$, $-COOCH_3$, and $-C(O)NR^9R^{10}$; wherein R^9 is H and R^{10} is selected from the group consisting of amino substituted C_{1-6} alkyl and $-(CH_2)_2NHC(O)O-t$ -butyl;

R⁵ is H; and

R⁶ is selected from the group consisting of H and halo.

20. The compound according to claim 1 wherein:

R¹ is selected from the group consisting of OH and -OCH₃;

R² is selected from the group consisting of OH, -OCH₃ and -O-(CH₂)₃NH₂;

R³ is C₁₋₆ alkyl;

R⁴ is selected from the group consisting of H, -COOH, -COOCH₃, -C(O)NH(CH₂)₂NH₂; and -C(O)NH(CH₂)₂NHC(O)O-*t*-butyl;

R⁵ is H; and

R⁶ is selected from the group consisting of H and bromo.

21. The compound according to claim 1 wherein:

R¹ is selected from the group consisting of OH and -OCH₃;

R² is selected from the group consisting of OH, -OCH₃ and -O-(CH₂)₃NH₂;


R³ is isopropyl;


R⁴ is selected from the group consisting of H, -COOH, -COOCH₃, -C(O)(CH₂)₂NH₂; and -C(O)NH(CH₂)₂NHC(O)O-*t*-butyl;

R⁵ is H; and

R⁶ is selected from the group consisting of H and bromo.


22. A compound selected from the group consisting of:





23. A compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

24. A compound of the formula:



25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24 and a pharmaceutically acceptable carrier or diluent.

26. A method of treating or preventing a condition in a mammal associated with AhR imbalance comprising administering to said mammal an effective amount of a compound according to any one of claims 1 to 24 or a composition of claim 25.

27. A method of treating or preventing an inflammatory disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to any one of claims 1 to 24 or a composition of claim 25.

28. The method according to claim 27 wherein the inflammatory disorder is selected from the group consisting of psoriasis, atopic dermatitis, vitiligo, acne,


neovascular (dry) AMD, neovascular (wet) AMD, uveitis or other inflammatory eye conditions, radiation dermatitis, COPD, asthma, multiple sclerosis (MS), and inflammatory bowel disease.

29. The method according to claim 28 wherein the compound, or a pharmaceutically acceptable salt, solvate or hydrate thereof, is administered topically.

30. The method of claim 28 wherein the inflammatory disorder is psoriasis or atopic dermatitis.

31. A method of treating or preventing psoriasis or atopic dermatitis in a subject in need thereof, comprising administering to the subject an effective amount of 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32. A compound of Formula (II)



wherein

each R^1 and R^2 is independently selected from the group consisting of OH, OR^7 , and H, provided that at least one of R^1 and R^2 is OH or OR^7 ;

R^7 is independently selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and acyl;

R^3 is selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{4-6} cycloalkenyl, halo, cyano, $-C(O)OR^8$, $-NR^9R^{10}$, $-S(O)_2NR^9R^{10}$, $-C(O)R^{11}$, $-OR^{12}$, $-S(O)_nR^{13}$ and optionally substituted heterocyclic ring;

n is an integer having a value of 0, 1 or 2;

R^6 is H;

R^8 is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;


each of R^9 and R^{10} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl; alternatively, R^9 and R^{10} together with the nitrogen atom to which they are attached, form a 5-7 membered cyclic saturated or unsaturated ring;

R^{11} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl; $-NR^9R^{10}$, and $-OR^{12}$;

each of R^{12} and R^{13} is independently is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl; and


R^6 is selected from the group consisting of halo, hydroxyl, alkoxy, optionally substituted C_{1-6} alkyl, halogenated alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, and optionally substituted aryl C_{1-6} alkyl.

33. Some embodiments describe a process for preparing a compound of Formula 8




or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising:

a) preparing a compound of Formula 5



or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising


1) alkylating 2,6-dihydroxyacetophenone or a pharmaceutically acceptable salt, solvate or hydrate thereof, to form a compound of Formula 2



2

or a pharmaceutically acceptable salt, solvate or hydrate thereof;


2) treating the ketone of Formula 2 or a pharmaceutically acceptable salt, solvate or hydrate thereof with a Grignard reagent, followed by elimination of water under acidic conditions to form a compound of Formula 3



3

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

3) hydrogenating the compound of Formula 3 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form a compound of Formula 4




4

or a pharmaceutically acceptable salt, solvate or hydrate thereof; and

4) borylating the compound of Formula 4 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form the compound of Formula 5

or a pharmaceutically acceptable salt, solvate or hydrate thereof;


b) preparing a compound of Formula 6



6

or a pharmaceutically acceptable salt, solvate or hydrate thereof comprising treating isoquinoline-3-ol with a triflating agent; and

c) coupling the compound of Formula 6 or a pharmaceutically acceptable salt, solvate or hydrate thereof with the compound of Formula 5 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form a compound of Formula 7



7

or a pharmaceutically acceptable salt, solvate or hydrate thereof; and

d) demethylating the compound of Formula 7 to form the compound of Formula 8, or a pharmaceutically acceptable salt, solvate or hydrate thereof; wherein steps a and b can be done in either order or simultaneously in different reaction vessels.

34. The process according to claim 33, further comprising purifying the compound of Formula 8.

35. The process according to claim 34 wherein the purifying comprises crystallization.